Loading patent…
AssigneeAlnylam Pharmaceuticals, Inc.
InventorsJayaprakash K. Nair, Justin Pierson, Elena Castellanos-Rizaldos, Yesseinia Anglero-Rodriguez, Karyn Schmidt, Lucas D. BonDurant, Kevin Dooley, Ivan Zlatev, Vasant R. Jadhav, Martin A. Maier, Alexander V. Kel'in, Masaaki Nakata
Estimating the term…
The present invention provides double stranded ribonucleic acid (dsRNA) agents for inhibiting expression of a target gene, comprising an antisense strand which is complementary to the target gene; a sense strand which is complementary to the antisense strand and forms a double stranded region with the antisense strand; and one or more C22 hydrocarbon chains conjugated to one or more internal positions on at least one strand, compositions comprising such dsRNA agents, and methods of use thereof for treating a subject having a skeletal muscle disorder, a cardiac muscle disorder, or an adipose tissue disorder.
A double stranded ribonucleic acid (dsRNA) agent for inhibiting expression of a target gene, comprising
-8. (canceled)
(canceled)
(canceled)
-20. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
(canceled)
A method of inhibiting expression of a target gene in a skeletal muscle cell, a cardiac muscle cell, or an adipocyte, comprising contacting the cell with a dsRNA agent that inhibits expression of a target gene, wherein the dsRNA agent comprises
-75. (canceled)
-84. (canceled)
(canceled)
(canceled)
A method of synthesizing a nucleoside monomer having the structure of Formula (I):
(canceled)
Dependencies are inferred from the claim text.